Community-Acquired Pneumonia: Comprehensive Management Algorithm
SLIDE 1: Diagnosis - Clinical Presentation & Confirmation
Diagnose CAP when patients present with cough, dyspnea, or pleuritic chest pain PLUS abnormal vital signs (fever, tachycardia) AND confirm with chest radiography or lung ultrasound 1, 2.
Key Diagnostic Points:
- Clinical features: Cough, fever, pleuritic pain, acute functional/cognitive decline in elderly
- Vital signs: Fever, tachycardia, tachypnea
- Imaging: Chest X-ray remains standard; lung ultrasound is emerging as rapid alternative 2
- Physical exam: Abnormal lung findings (crackles, bronchial breath sounds, dullness to percussion)
SLIDE 2: Severity Assessment - Site of Care Decision
Use validated severity scores immediately to determine outpatient versus inpatient management 1, 3.
Severity Stratification:
- Outpatient: Low-risk patients without severe criteria
- Inpatient (non-ICU): Moderate severity with comorbidities or clinical instability
- ICU admission criteria (severe CAP):
- Requiring mechanical ventilation
- Septic shock requiring vasopressors
- ≥3 minor criteria: respiratory rate >30, PaO2/FiO2 <250, multilobar infiltrates, confusion, uremia, leukopenia, thrombocytopenia, hypothermia, hypotension requiring aggressive fluid resuscitation
Additional Risk Stratification:
- Consider serum lactate for further risk assessment 4
- Procalcitonin may assist with severity determination 3
SLIDE 3: Diagnostic Testing - Who Needs What
Do NOT routinely test all CAP patients; reserve microbiological testing for severe CAP and specific clinical scenarios 1.
Outpatients:
Hospitalized Patients (Non-ICU):
- Blood cultures before antibiotics
- Sputum culture if good quality specimen available
Severe CAP (ICU):
- Blood cultures (mandatory)
- Sputum cultures on selective media
- Pneumococcal urinary antigen 1
- Legionella urinary antigen PLUS lower respiratory tract secretions for Legionella culture or nucleic acid testing 1
- Consider Legionella testing if: outbreak association, recent travel, or severe CAP
Caveat: Urinary antigen testing showed 57% reduced odds of mortality in observational studies when used for severe CAP 1
SLIDE 4: Empiric Antibiotic Selection - Outpatients
For outpatients WITHOUT comorbidities: Use amoxicillin 1g three times daily, OR doxycycline 100mg twice daily, OR macrolide (only if local pneumococcal resistance <25%) 1.
Outpatients WITH Comorbidities*:
Choose ONE of these regimens:
Option 1 - Combination therapy:
- Beta-lactam: Amoxicillin/clavulanate 875/125mg twice daily OR cefpodoxime 200mg twice daily
- PLUS macrolide (azithromycin 500mg day 1, then 250mg daily) OR doxycycline 100mg twice daily
Option 2 - Monotherapy:
- Respiratory fluoroquinolone: Levofloxacin 750mg daily OR moxifloxacin 400mg daily OR gemifloxacin 320mg daily
*Comorbidities: chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancy, asplenia
Critical Pitfall: Avoid fluoroquinolones if patient used antibiotics in past 90 days (resistance risk)
SLIDE 5: Empiric Antibiotic Selection - Hospitalized (Non-ICU)
For hospitalized non-ICU patients: Use respiratory fluoroquinolone alone OR beta-lactam PLUS macrolide combination 1, 5.
Preferred Regimens:
Option 1 - Fluoroquinolone monotherapy:
- Levofloxacin 750mg IV/PO daily
- Moxifloxacin 400mg IV/PO daily
Option 2 - Combination therapy:
- Beta-lactam: Ceftriaxone 1-2g IV daily OR ampicillin-sulbactam 1.5-3g IV q6h
- PLUS macrolide: Azithromycin 500mg IV/PO daily
Rationale: Combination therapy covers both typical and atypical pathogens; fluoroquinolone monotherapy provides same coverage with single agent
SLIDE 6: Empiric Antibiotic Selection - Severe CAP (ICU)
For ICU patients: ALWAYS use combination therapy with beta-lactam PLUS either azithromycin OR respiratory fluoroquinolone 1, 5.
Standard Severe CAP Regimen:
- Beta-lactam: Ceftriaxone 2g IV daily OR cefotaxime 1-2g IV q8h
- PLUS azithromycin 500mg IV daily OR respiratory fluoroquinolone (levofloxacin 750mg IV daily)
Risk Factors for Pseudomonas:
- Prior respiratory isolation of Pseudomonas
- Recent hospitalization PLUS parenteral antibiotics in last 90 days
- Structural lung disease (bronchiectasis)
If Pseudomonas risk present:
- Antipseudomonal beta-lactam: Piperacillin-tazobactam 4.5g IV q6h OR cefepime 2g IV q8h OR meropenem 1g IV q8h
- PLUS aminoglycoside (gentamicin or tobramycin) OR antipseudomonal fluoroquinolone (levofloxacin or ciprofloxacin)
- PLUS azithromycin 500mg IV daily
Risk Factors for MRSA:
- Prior respiratory isolation of MRSA
- Recent hospitalization with parenteral antibiotics in last 90 days
- Cavitary infiltrates
- Post-influenza pneumonia
If MRSA risk present, ADD:
- Vancomycin 15-20mg/kg IV q8-12h (target trough 15-20) OR linezolid 600mg IV q12h OR ceftaroline 600mg IV q12h 3, 5
SLIDE 7: Step-Down Therapy - IV to Oral Transition
Switch from IV to oral antibiotics when patients show clinical improvement AND can tolerate oral medications, typically within first 3 days 5.
Clinical Stability Criteria (must meet ALL):
- Temperature ≤37.8°C
- Heart rate ≤100 bpm
- Respiratory rate ≤24 breaths/min
- Systolic blood pressure ≥90 mmHg
- Oxygen saturation ≥90% on room air
- Able to take oral medications
- Normal mental status
Transition Strategy:
- Switch to oral equivalent of IV regimen
- Continue same antibiotic class when possible
- Complete total duration with oral therapy
Common Pitfall: Do NOT wait for complete radiographic resolution before switching to oral therapy—clinical improvement is sufficient 6
SLIDE 8: Antibiotic Duration
Treat CAP for shorter durations based on clinical stability rather than fixed 7-10 day courses 2, 6.
Duration Guidelines:
Uncomplicated CAP:
- 5 days minimum if patient achieves clinical stability 2
- May extend if slow clinical response
Severe CAP or Complicated Cases:
- Typically 7-10 days
- Longer duration if:
- Bacteremia present
- Pseudomonas or MRSA infection
- Empyema or abscess formation
- Slow clinical response
Clinical Stability Criteria for Stopping:
- Afebrile for 48-72 hours
- Improving respiratory symptoms
- Hemodynamically stable
- Able to maintain oral intake
Key Point: Biomarker-guided therapy (procalcitonin) may help determine duration but requires validation 6
SLIDE 9: Adjunctive Treatment - Corticosteroids
Administer corticosteroids within 36 hours of admission for severe CAP to decrease ARDS risk and treatment duration, BUT avoid in influenza pneumonia 3, 7.
Corticosteroid Use:
Indications for corticosteroids:
- Severe CAP requiring ICU admission
- Marked inflammatory syndrome
- Septic shock from pneumonia
Typical regimen:
- Methylprednisolone 0.5mg/kg IV q12h for 5 days
- OR equivalent corticosteroid dose
ABSOLUTE CONTRAINDICATION:
- Influenza pneumonia - corticosteroids worsen outcomes 7
Evidence Considerations:
- Three recent large RCTs showed conflicting results 7
- Benefits: Reduced ARDS, shorter length of stay
- Risks: Hyperglycemia, secondary infections
- Best candidates: Patients with marked inflammatory response without influenza 7
Critical Pitfall: Always test for influenza before starting corticosteroids in severe CAP
SLIDE 10: Adjunctive Treatment - Respiratory Support
Provide tailored respiratory support based on severity: supplemental oxygen for hypoxemia, high-flow nasal cannula for moderate hypoxemic failure, mechanical ventilation for severe respiratory failure 7.
Respiratory Support Algorithm:
Mild hypoxemia (SpO2 88-92%):
- Supplemental oxygen via nasal cannula or face mask
- Target SpO2 >90%
Moderate hypoxemic failure:
- High-flow nasal cannula (HFNC)
- Non-invasive ventilation (NIV) - use cautiously, high failure rate in pneumonia
Severe respiratory failure:
- Mechanical ventilation with lung-protective strategies
- Tidal volume 6-8 mL/kg predicted body weight
- Plateau pressure <30 cmH2O
- Consider prone positioning if PaO2/FiO2 <150
Fluid Management:
- Early aggressive fluid resuscitation for septic shock
- Conservative fluid strategy once hemodynamically stable
- Avoid fluid overload (worsens oxygenation)
SLIDE 11: Special Considerations - Viral Pneumonia
If respiratory virus testing is positive, continue antibacterial therapy unless there is high certainty of pure viral etiology with no bacterial co-infection 2.
Viral-Bacterial Co-infection:
- Common with influenza, COVID-19, RSV
- Bacterial superinfection occurs in 10-30% of viral pneumonia
- Do NOT stop antibiotics based solely on positive viral test 2
Influenza-Specific Management:
- Start oseltamivir 75mg PO twice daily within 48 hours of symptom onset
- Continue antibacterial coverage for bacterial co-infection
- Avoid corticosteroids (worsens outcomes) 7
COVID-19 Pneumonia:
- Follow separate COVID-19 treatment guidelines
- Consider bacterial co-infection if severe or prolonged course
- Antibiotics often appropriate in hospitalized patients
SLIDE 12: Follow-Up Imaging
Obtain follow-up chest imaging in 6-12 weeks for high-risk patients: age >50, smokers, or those with persistent symptoms 1.
Indications for Follow-Up Imaging:
Mandatory follow-up CXR:
- Age >50 years with risk factors for lung cancer
- Current or former smokers
- Persistent symptoms after treatment completion
- Slow clinical response
- Recurrent pneumonia in same location
Timing:
- 6-12 weeks after treatment completion
- Allows time for radiographic resolution
- Earlier imaging if clinical deterioration
Purpose:
- Exclude underlying malignancy (especially lung cancer)
- Confirm radiographic resolution
- Identify complications (empyema, abscess)
Common Pitfall: Radiographic resolution lags behind clinical improvement by 4-6 weeks—do NOT repeat imaging during treatment unless clinical deterioration occurs
SLIDE 13: Prevention Strategies
Vaccinate all eligible patients with pneumococcal vaccines (PCV13, PPSV23) and annual influenza vaccine to prevent CAP and reduce severity 3, 5.
Pneumococcal Vaccination:
Adults ≥65 years:
- PCV13 (Prevnar 13) followed by PPSV23 (Pneumovax 23) ≥1 year later
- OR newer PCV15/PCV20 per updated guidelines
Adults 19-64 years with risk factors:
- Chronic heart/lung/liver disease
- Diabetes, alcoholism
- Immunocompromising conditions
- Smoking
Influenza Vaccination:
- Annual vaccination for all adults
- Especially critical for high-risk groups
- Reduces pneumonia incidence and severity
Additional Prevention:
- Smoking cessation counseling
- Optimize management of chronic diseases
- Hand hygiene education
Evidence: Vaccination reduces invasive pneumococcal disease and CAP-related mortality 3, 5
SLIDE 14: Management Pitfalls to Avoid
Critical Errors in CAP Management:
Diagnostic Pitfalls:
- ❌ Over-testing low-risk outpatients (unnecessary cost, no benefit)
- ❌ Under-testing severe CAP (miss resistant organisms)
- ❌ Delaying antibiotics while awaiting test results
Treatment Pitfalls:
- ❌ Using macrolide monotherapy where pneumococcal resistance >25%
- ❌ Missing MRSA/Pseudomonas risk factors (inadequate coverage)
- ❌ Fluoroquinolone use in patients with recent antibiotic exposure
- ❌ Stopping antibiotics based on positive viral test alone 2
- ❌ Corticosteroids in influenza pneumonia 7
Management Pitfalls:
- ❌ Delaying IV-to-oral switch despite clinical stability
- ❌ Prolonging antibiotics beyond clinical stability
- ❌ Repeating chest imaging during treatment (unless deterioration)
- ❌ Discharging high-risk patients without follow-up imaging plan
SLIDE 15: Quality Improvement Measures
Adherence to IDSA/ATS guidelines improves patient outcomes including mortality, length of stay, and treatment success 5.
Key Performance Indicators:
Time-Sensitive Measures:
- Antibiotics within 4-6 hours of presentation
- Blood cultures before antibiotics (if indicated)
- ICU admission within 4 hours for severe CAP
Guideline Concordance:
- Appropriate empiric antibiotic selection
- Correct site-of-care decision
- Appropriate diagnostic testing (not over- or under-testing)
Outcome Measures:
- 30-day mortality
- Length of hospital stay
- Readmission rates
- Time to clinical stability
Antibiotic Stewardship:
- De-escalation based on culture results
- Shortest effective duration
- IV-to-oral conversion when appropriate
- Avoid unnecessary broad-spectrum coverage
Evidence: Guideline-concordant care associated with 57% reduced mortality in severe CAP 1